NASDAQ
KPTI

Karyopharm Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Karyopharm Therapeutics Inc Stock Price

Vitals

Today's Low:
$1.19
Today's High:
$1.31
Open Price:
$1.2
52W Low:
$1.13
52W High:
$6.01
Prev. Close:
$1.22
Volume:
1085248

Company Statistics

Market Cap.:
$139.51 million
Book Value:
-0.623
Revenue TTM:
$146.00 million
Operating Margin TTM:
-79.3%
Gross Profit TTM:
$151.86 million
Profit Margin:
-96.98%
Return on Assets TTM:
-26.11%
Return on Equity TTM:
-891.05%

Company Profile

Karyopharm Therapeutics Inc had its IPO on 2013-11-06 under the ticker symbol KPTI.

The company operates in the Healthcare sector and Biotechnology industry. Karyopharm Therapeutics Inc has a staff strength of 385 employees.

Stock update

Shares of Karyopharm Therapeutics Inc opened at $1.2 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.19 - $1.31, and closed at $1.29.

This is a +5.74% increase from the previous day's closing price.

A total volume of 1,085,248 shares were traded at the close of the day’s session.

In the last one week, shares of Karyopharm Therapeutics Inc have slipped by -5.15%.

Karyopharm Therapeutics Inc's Key Ratios

Karyopharm Therapeutics Inc has a market cap of $139.51 million, indicating a price to book ratio of 12.0484 and a price to sales ratio of 1.0495.

In the last 12-months Karyopharm Therapeutics Inc’s revenue was $146.00 million with a gross profit of $151.86 million and an EBITDA of $-115112000. The EBITDA ratio measures Karyopharm Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Karyopharm Therapeutics Inc’s operating margin was -79.3% while its return on assets stood at -26.11% with a return of equity of -891.05%.

In Q2, Karyopharm Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 5.3%.

Karyopharm Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.15

Its diluted EPS in the last 12-months stands at $-1.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.15. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Karyopharm Therapeutics Inc’s profitability.

Karyopharm Therapeutics Inc stock is trading at a EV to sales ratio of 1.6519 and a EV to EBITDA ratio of -6.8543. Its price to sales ratio in the trailing 12-months stood at 1.0495.

Karyopharm Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$297.83 million
Total Liabilities
$58.93 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Karyopharm Therapeutics Inc ended 2024 with $297.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $297.83 million while shareholder equity stood at $-71248000.00.

Karyopharm Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $58.93 million in other current liabilities, 12000.00 in common stock, $-1410695000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $80.89 million and cash and short-term investments were $236.77 million. The company’s total short-term debt was $3,084,000 while long-term debt stood at $170.50 million.

Karyopharm Therapeutics Inc’s total current assets stands at $291.38 million while long-term investments were $0 and short-term investments were $155.87 million. Its net receivables were $32.28 million compared to accounts payable of $2.29 million and inventory worth $3.67 million.

In 2024, Karyopharm Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Karyopharm Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.29
52-Week High
$6.01
52-Week Low
$1.13
Analyst Target Price
$7.11

Karyopharm Therapeutics Inc stock is currently trading at $1.29 per share. It touched a 52-week high of $6.01 and a 52-week low of $6.01. Analysts tracking the stock have a 12-month average target price of $7.11.

Its 50-day moving average was $1.56 and 200-day moving average was $2.81 The short ratio stood at 4.11 indicating a short percent outstanding of 0%.

Around 500.7% of the company’s stock are held by insiders while 7363.3% are held by institutions.

Frequently Asked Questions About Karyopharm Therapeutics Inc

The stock symbol (also called stock or share ticker) of Karyopharm Therapeutics Inc is KPTI

The IPO of Karyopharm Therapeutics Inc took place on 2013-11-06

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$15.98
1.96
+13.97%
$0.22
-0.03
-10.63%
$1.18
0.02
+1.72%
$0.09
0
+0.11%
$987.15
-9.3
-0.93%
$16.53
0.78
+4.95%
$38.95
-0.46
-1.17%
$3.8
0.08
+2.15%
$20.89
0.71
+3.52%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Address

85 Wells Avenue, Newton, MA, United States, 02459